PeptideDB

ACT-777991 1967811-46-6

ACT-777991 1967811-46-6

CAS No.: 1967811-46-6

ACT-777991 is a selective CXCR3 antagonist. ACT-777991 displays microsomal and hepatocyte stability in animal models. AC
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

ACT-777991 is a selective CXCR3 antagonist. ACT-777991 displays microsomal and hepatocyte stability in animal models. ACT-777991 inhibits the migration of activated T cells toward CXCL11.

Physicochemical Properties


Molecular Formula C20H20F6N8O2S
Molecular Weight 550.480622291565
Exact Mass 550.133
CAS # 1967811-46-6
PubChem CID 121485701
Appearance White to off-white solid powder
LogP 2.5
Hydrogen Bond Donor Count 1
Hydrogen Bond Acceptor Count 15
Rotatable Bond Count 6
Heavy Atom Count 37
Complexity 787
Defined Atom Stereocenter Count 1
SMILES

CC1=NN(C=N1)CC(=O)N2CCN(C[C@H]2CCO)C3=C(N=C(S3)C(F)(F)F)C4=CN=C(N=C4)C(F)(F)F

InChi Key FDZFVXKCJKOSRC-CYBMUJFWSA-N
InChi Code

InChI=1S/C20H20F6N8O2S/c1-11-29-10-33(31-11)9-14(36)34-4-3-32(8-13(34)2-5-35)16-15(30-18(37-16)20(24,25)26)12-6-27-17(28-7-12)19(21,22)23/h6-7,10,13,35H,2-5,8-9H2,1H3/t13-/m1/s1
Chemical Name

1-[(2R)-2-(2-hydroxyethyl)-4-[2-(trifluoromethyl)-4-[2-(trifluoromethyl)pyrimidin-5-yl]-1,3-thiazol-5-yl]piperazin-1-yl]-2-(3-methyl-1,2,4-triazol-1-yl)ethanone
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


ln Vitro In CHO cells, ACT-777991 suppresses hEGR with an IC50 value of 26 μM[1]. The drug ACT-777991 (1 μM; 45 min) exhibits stability in hepatocytes and microsomes from dogs, humans, and scaffolds. Mouse T cell movement toward CXCL11 is inhibited and activated by 777991 (0.01-1 μM), with IC50 ranges of 3.2-64 nM and 4.9-21 nM, respectively [1]. CXCR3-induced mouse T cell chemotaxis is inhibited by ACT-777991 (1 nM, 5 nM, 20 nM, and 50 nM) [1].
ln Vivo ACT-777991 (0.5 mg/kg, 1 mg/kg; i.v.; single dosage) exhibited low mid-vessel clarity in a cohort of Wistar stents (14/156) or Beagle dogs (5/15) [1] . ACT-777991 (0.006-2 mg/g meal; sidewall; starts 3 days before LPS treatment and stops 72 hours after LPS treatment) replicates the chemotaxis of CXCR3+ T cells in the model [1]
Animal Protocol Animal/Disease Models: Mouse LPS challenge model [1]
Doses: 0.006, 0.02, 0.06, 0.2, 0.6, 2 mg per g of food
Route of Administration: PO;. Beginning 3 days before LPS challenge and continuing until the end of the study (72 hrs (hrs (hours)) after LPS challenge)
Experimental Results: Reduction in the number of BAL CD8+ T cells in a dose-dependent manner.
References

[1]. Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies. J Med Chem. 2023 Mar 23;66(6):4179-4196.


Solubility Data


Solubility (In Vitro) May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo) Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)

Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.8166 mL 9.0830 mL 18.1660 mL
5 mM 0.3633 mL 1.8166 mL 3.6332 mL
10 mM 0.1817 mL 0.9083 mL 1.8166 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.